Published On: 1/10/2019

TARGET PharmaSolutions to advance NASH Research through new collaboration

TARGET PharmaSolutions, Inc., a real-world data solutions company, is pleased to announce that Novartis has entered into a long-term strategic alliance for TARGET-NASH.

TARGET-NASH is a longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH will enroll up to 15,000 patients over the coming years.  TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).

Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Novartis join TARGET-NASH. TARGET-NASH has enrolled a large, diverse patient population and is generating valuable real-world data and insight on NASH, including the natural history of the disease and current treatment patterns.    The TARGET real-world data solution which includes a biorepository and patient reported outcomes is a critical resource for our collaborators as they work to better understand and to combat this rapidly growing disease.”

TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process.  The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.  This model enables TARGET’s stakeholders to answer critical strategic and planning questions.  The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes.